NCT04268823View on ClinicalTrials.gov

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

September 13, 2022

Study Completion Date

September 20, 2022

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

QBW251

Capsule 300mg

DRUG

Placebo

Capsule 300mg

Trial Locations (12)

4031

Novartis Investigative Site, Basel

8091

Novartis Investigative Site, Zurich

8330

Novartis Investigative Site, Feldbach

9007

Novartis Investigative Site, Sankt Gallen

10119

Novartis Investigative Site, Berlin

10969

Novartis Investigative Site, Berlin

55128

Novartis Investigative Site, Mainz

58452

Novartis Investigative Site, Witten

60596

Novartis Investigative Site, Frankfurt

69126

Novartis Investigative Site, Heidelberg

BD9 6RJ

Novartis Investigative Site, Bradford

SW3 6HP

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY